Interleukin-18 treatment options for inflammatory diseases

References

• Okamura H, Tsutsui H, Komatsu T et al. Cloning of a new cytokine that induces interferon-γ. Nature 378, 88–91 (1995).
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E et al. A novel interleukin-l-like cytokine (IL-33) that signals via the IL-1 receptor-related protein ST2 and induces T helper Type 2-associated cytokines. Immunity (2005) (In press).
   Google Scholar
• Ghayur T, Banerjee S, Hugunin M et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-γ production. Nature 386, 619–623 (1997).
   PubMed Web of Science ®Google Scholar
• Gu Y, Kuida K, Tsutsui H et al. Activation of IFN-γ inducing factor mediated by interleukin-1β converting enzyme. Science 275, 206–209 (1997).
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Newton K, Monack DM et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430, 213–218 (2004).
   PubMed Web of Science ®Google Scholar
• Fantuzzi G, Puren AJ, Harding MW, Livingston DJ, Dinarello CA. IL-18 regulation of IFN-γ production and cell proliferation as revealed in interleukin-1β converting enzyme-deficient mice. Blood 91, 2118–2125 (1998).
   PubMedGoogle Scholar
• Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 12, 53–72 (2001).
   PubMed Web of Science ®Google Scholar
• Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA. IL-1β-converting enzyme (caspase-1) in intestinal inflammation. Proc. Natl Acad. Sci. USA 98, 13249–13254 (2001).
   PubMed Web of Science ®Google Scholar
• Siegmund B, Fantuzzi G, Rieder F et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, R1264–R1273 (2001).
   PubMedGoogle Scholar
• Gatti S, Beck J, Fantuzzi G, Bartfai T, Dinarello CA. Effect of interleukin-18 on mouse core body temperature. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282, R702–R709 (2002).
   PubMedGoogle Scholar
• Li S, Goorha S, Ballou LR, Blatteis CM. Intracerebroventricular interleukin-6, macrophage inflammatory protein-1 β and IL-18: pyrogenic and PGE(2)-mediated? Brain Res. 992, 76–84 (2003).
   PubMedGoogle Scholar
• Reznikov LL, Kim SH, Westcott JY et al. IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-γ. Proc. Natl Acad. Sci. USA 97, 2174–2179 (2000).
   PubMed Web of Science ®Google Scholar
• Lee JK, Kim SH, Lewis EC, Azam T, Reznikov LL, Dinarello CA. Differences in signaling pathways by IL-1beta and IL-18. Proc. Natl Acad. Sci. USA 101, 8815–8820 (2004).
   PubMed Web of Science ®Google Scholar
• Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNF-α. Immunity 22, 131–142 (2005).
   PubMed Web of Science ®Google Scholar
• Joosten LA, van De Loo FA, Lubberts E et al. An IFN-γ-independent pro-inflammatory role of IL-18 in murine streptococcal cell wall arthritis. J. Immunol. 165, 6553–6558 (2000).
   PubMed Web of Science ®Google Scholar
• Carrascal MT, Mendoza L, Valcarcel M et al. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res. 63, 491–497 (2003).
   PubMed Web of Science ®Google Scholar
• Randle JC, Harding MW, Ku G, Schonharting M, Kurrle R. ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin. Investig. Drugs 10, 1207–1209 (2001).
   PubMed Web of Science ®Google Scholar
• Novick D, Kim S-H, Fantuzzi G, Reznikov L, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 10, 127–136 (1999).
   PubMed Web of Science ®Google Scholar
• Novick D, Schwartsburd B, Pinkus R et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14, 334–342 (2001).
   PubMed Web of Science ®Google Scholar
• Kim S-H, Eisenstein M, Reznikov L et al. Structural requirements of six naturally occurring isoforms of the interleukin-18 binding protein to inhibit interleukin-18. Proc. Natl Acad. Sci. USA 97, 1190–1195 (2000).
   PubMed Web of Science ®Google Scholar
• Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β processing inflammasome with increased activity in Muckle-Wells auto-inflammatory disorder. Immunity 20, 319–325 (2004).
   PubMed Web of Science ®Google Scholar
• Aganna E, Martinon F, Hawkins PN et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum. 46, 2445–2452 (2002).
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50, 607–612 (2004).
   PubMed Web of Science ®Google Scholar
• Coeshott C, Ohnemus C, Pilyavskaya A et al. Converting enzyme-independent release of TNF α and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase-3. Proc. Natl Acad. Sci. USA 96, 6261–6266 (1999).
   PubMed Web of Science ®Google Scholar
• Sugawara S, Uehara A, Nochi T et al. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J. Immunol. 167, 6568–6575. (2001).
   PubMed Web of Science ®Google Scholar
• Faggioni R, Cattley RC, Guo J et al. IL-18-binding protein protects against lipopolysaccharide-induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice. J. Immunol. 167, 5913–5920 (2001).
   PubMedGoogle Scholar
• Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc. Natl Acad. Sci. USA 98, 2871–2876 (2001).
   PubMed Web of Science ®Google Scholar
• Melnikov VY, Ecder T, Fantuzzi G et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J. Clin. Invest. 107, 1145–1152 (2001).
   PubMed Web of Science ®Google Scholar
• Perregaux DG, McNiff P, Laliberte R, Conklyn M, Gabel CA. ATP acts as an agonist to promote stimulus-induced secretion of IL-1 β and IL-18 in human blood. J. Immunol. 165, 4615–4623 (2000).
   PubMed Web of Science ®Google Scholar
• Solle M, Labasi J, Perregaux DG et al. Altered cytokine production in mice lacking P2X(7) receptors. J. Biol. Chem. 276, 125–132 (2001).
   PubMed Web of Science ®Google Scholar
• Laliberte RE, Eggler J, Gabel CA. ATP treatment of human monocytes promotes caspase-1 maturation and externalization. J. Biol. Chem. 274, 36944–36951 (1999).
   PubMed Web of Science ®Google Scholar
• Baraldi PG, del Carmen Nunez M, Morelli A, Falzoni S, Di Virgilio F, Romagnoli R. Synthesis and biologic activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor. J. Med. Chem. 46, 1318–1329 (2003).
   PubMed Web of Science ®Google Scholar
• Gardella S, Andrei C, Costigliolo S, Poggi A, Zocchi MR, Rubartelli A. Interleukin-18 synthesis and secretion by dendritic cells are modulated by interaction with antigen-specific T cells. J. Leukoc. Biol. 66, 237–241 (1999).
   PubMed Web of Science ®Google Scholar
• Gardella S, Andrei C, Poggi A, Zocchi MR, Rubartelli A. Control of interleukin-18 secretion by dendritic cells: role of calcium influxes. FEBS Lett. 481, 245–248 (2000).
   PubMed Web of Science ®Google Scholar
• Kato Z, Jee J, Shikano H et al. The structure and binding mode of interleukin-18. Nature Struct. Biol. 10, 966–971 (2003).
   PubMedGoogle Scholar
• Azam T, Novick D, Bufler P et al. Identification of a critical Ig-like domain in IL-18 receptor alpha and characterization of a functional IL-18 receptor complex. J. Immunol. 171, 6574–6580 (2003).
   PubMed Web of Science ®Google Scholar
• Casadio R, Frigimelica E, Bossu P et al. Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1β/IL-1R(I) complex. FEBS Lett. 499, 65–68 (2001).
   PubMed Web of Science ®Google Scholar
• Reznikov LL, Kim SH, Zhou L et al. The combination of soluble IL-18Ra and IL-18Rb chains inhibits IL-18-Induced IFN-g. J. Interferon Cytokine Res. 22, 593–601 (2002).
   PubMed Web of Science ®Google Scholar
• Kumar S, McDonnell PC, Lehr R et al. Identification and initial characterization of four novel members of the interleukin-1 family. J. Biol. Chem. 275, 10308–10314 (2000).
   PubMed Web of Science ®Google Scholar
• Pan G, Risser P, Mao W et al. IL-1H, an interleukin-1-related protein that binds IL-18 receptor/IL- 1Rrp. Cytokine 13, 1–7 (2001).
   PubMed Web of Science ®Google Scholar
• Kumar S, Hanning CR, Brigham-Burke MR et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-γ production. Cytokine 18, 61–71 (2002).
   PubMed Web of Science ®Google Scholar
• Bufler P, Azam T, Gamboni-Robertson F et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc. Natl Acad. Sci. USA 99, 13723–13728 (2002).
   PubMed Web of Science ®Google Scholar
• Novick D, Engelmann H, Wallach D, Leitner O, Revel M, Rubinstein M. Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J. Chromatogr. 510, 331–337 (1990).
   PubMed Web of Science ®Google Scholar
• Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J. Biol. Chem. 265, 1531–1536 (1990).
   PubMed Web of Science ®Google Scholar
• Kim SH, Azam T, Novick D et al. Identification of amino acid residues critical for biological activity in human interleukin-18. J. Biol. Chem. 14, 14 (2002).
   Google Scholar
• Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum. 52, 1960–1967 (2005).
   PubMed Web of Science ®Google Scholar
• Hurgin V, Novick D, Rubinstein M. The promoter of IL-18 binding protein: activation by an IFN-γ-induced complex of IFN regulatory factor 1 and CCAAT/enhancer binding protein beta. Proc. Natl Acad. Sci. USA 99, 16957–16962 (2002).
   PubMedGoogle Scholar
• Paulukat J, Bosmann M, Nold M et al. Expression and release of IL-18 binding protein in response to IFN-γ. J. Immunol. 167, 7038–7043 (2001).
   PubMed Web of Science ®Google Scholar
• Fantuzzi G, Reed D, Qi M, Scully S, Dinarello CA, Senaldi G. Role of interferon regulatory factor-1 in the regulation of IL-18 production and activity. Eur. J. Immunol. 31, 369–375 (2001).
   PubMed Web of Science ®Google Scholar
• Siegmund B, Sennello JA, Lehr HA, Senaldi G, Dinarello CA, Fantuzzi G. Interferon regulatory factor-1 as a protective gene in intestinal inflammation: role of TCR γ δ T cells and interleukin-18-binding protein. Eur. J. Immunol. 34, 2356–2364 (2004).
   PubMedGoogle Scholar
• Xiang Y, Moss B. Correspondence of the functional epitopes of poxvirus and human interleukin-18-binding proteins. J. Virol. 75, 9947–9954 (2001).
   PubMed Web of Science ®Google Scholar
• Xiang Y, Moss B. Determination of the functional epitopes of human interleukin-18-binding protein by site-directed mutagenesis. J. Biol. Chem. 276, 17380–17386 (2001).
   PubMedGoogle Scholar
• Maeno N, Takei S, Imanaka H et al. Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome. Arthritis Rheum. 50, 1935–1938 (2004).
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Differences between antitumor necrosis factor-α monoclonal antibodies and soluble TNF receptors in host defense impairment. J. Rheumatol. Suppl. 74, 40–47 (2005).
   PubMedGoogle Scholar
• Ottenhoff TH, Verreck FA, Lichtenauer-Kaligis EG, Hoeve MA, Sanal O, van Dissel JT. Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nature Genet. 32, 97–105 (2002).
   PubMedGoogle Scholar
• Wei XQ, Leung BP, Arthur HM, McInnes IB, Liew FY. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J. Immunol. 166, 517–521 (2001).
   PubMed Web of Science ®Google Scholar
• Plater-Zyberk C, Joosten LA, Helsen MM et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J. Clin. Invest. 108, 1825–1832 (2001).
   PubMed Web of Science ®Google Scholar
• Bossu P, Neumann D, Del Giudice E et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc. Natl Acad. Sci. USA 100, 14181–14186 (2003).
   PubMed Web of Science ®Google Scholar
• Kim SH, Reznikov LL, Stuyt RJ et al. Functional reconstitution and regulation of IL-18 activity by the IL- 18R β chain. J. Immunol. 166, 148–154 (2001).
   PubMed Web of Science ®Google Scholar
• Neumann D, Martin MU. Interleukin-12 upregulates the IL-18Rb chain in BALB/c thymocytes. J. Interferon Cytokine Res. 21, 635–642 (2001).
   PubMedGoogle Scholar
• Lugo-Villarino G, Maldonado-Lopez R, Possemato R, Penaranda C, Glimcher LH. T-bet is required for optimal production of IFN-γ and antigen-specific T cell activation by dendritic cells. Proc. Natl Acad. Sci. USA 100, 7749–7754 (2003).
   PubMed Web of Science ®Google Scholar
• Cardoso SM, DeFor TE, Tilley LA, Bidwell JL, Weisdorf DJ, MacMillan ML. Patient interleukin-18 GCG haplotype associates with improved survival and decreased transplant-related mortality after unrelated-donor bone marrow transplantation. Br. J. Haematol. 126, 704–710 (2004).
   PubMed Web of Science ®Google Scholar
• Min CK, Maeda Y, Lowler K et al. Paradoxical effects of interleukin-18 on the severity of acute graft versus host disease mediated by CD4+ and CD8+ T cell subsets after experimental allogeneic bone marrow transplantation. Blood 104, 3393–3399 (2004).
   PubMedGoogle Scholar
• Reddy P, Ferrara JL. Role of interleukin-18 in acute graft versus host disease. J. Lab. Clin. Med. 141, 365–371 (2003).
   PubMedGoogle Scholar
• Hoshino T, Yagita H, Ortaldo JR, Wiltrout RH, Young HA. In vivo administration of IL-18 can induce IgE production through Th2 cytokine induction and upregulation of CD40 ligand (CD154) expression on CD4+ T cells. Eur. J. Immunol. 30, 1998–2006 (2000).
   PubMed Web of Science ®Google Scholar
• Kawase Y, Hoshino T, Yokota K et al. Exacerbated and prolonged allergic and non-allergic inflammatory cutaneous reaction in mice with targeted interleukin-18 expression in the skin. J. Invest. Dermatol. 121, 502–509 (2003).
   PubMed Web of Science ®Google Scholar
• Konishi H, Tsutsui H, Murakami T et al. IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc. Natl Acad. Sci. USA 99, 11340–11345 (2002).
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 19, 423–474 (2001).
   PubMed Web of Science ®Google Scholar
• Kaser A, Kaser S, Kaneider NC, Enrich B, Wiedermann CJ, Tilg H. Interleukin-18 attracts plasmacytoid dendritic cells (DC2s) and promotes Th1 induction by DC2s through IL-18 receptor expression. Blood 103, 648–655 (2004).
   PubMed Web of Science ®Google Scholar
• Raeburn CD, Dinarello CA, Zimmerman MA et al. Neutralization of IL-18 attenuates lipopolysaccharide-induced myocardial dysfunction. Am. J. Physiol. 283, H650–H657 (2002).
   PubMed Web of Science ®Google Scholar
• Friteau L, Francesconi E, Lando D, Dugas B, Damais C. Opposite effect of interferon-γ on PGE2 release from interleukin-1-stimulated human monocytes or fibroblasts. Biochem. Biophys. Res. Commun. 157, 1197–1204 (1988).
   PubMedGoogle Scholar
• Mallat Z, Heymes C, Corbaz A et al. Evidence for altered interleukin (IL)-18 pathway in human heart failure. FASEB J. (2004).
   PubMedGoogle Scholar
• Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ. Res. 90, E34–E38 (2002).
   PubMed Web of Science ®Google Scholar
• Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J. Exp. Med. 195, 245–257 (2002).
   PubMed Web of Science ®Google Scholar
• Mallat Z, Corbaz A, Scoazec A et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ. Res. 89, E41–E45 (2001).
   PubMed Web of Science ®Google Scholar
• Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am. J. Kidney Dis. 43, 405–414 (2004).
   PubMed Web of Science ®Google Scholar
• Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the ICU. J. Am. Soc. Nephrol. (2005) (In Press).
   Google Scholar
• Mazodier K, Marin V, Novick D et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood (2005) [Epub ahead of print].
   PubMedGoogle Scholar
• Mencacci A, Bacci A, Cenci E et al. interleukin-18 restores defective Th1 immunity to Candida albicans in caspase 1-deficient mice. Infect. Immun. 68, 5126–5131. (2000).
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α-neutralizing agent. N. Engl. J. Med. 345, 1098–1104 (2001).
   PubMed Web of Science ®Google Scholar
• Mohan AK, Cote TR, Block JA, Manadan AM, Siegel J, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin. Infect. Dis. 39, 295–299 (2004).
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38, 1261–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Ehlers S, Benini J, Kutsch S, Endres R, Rietschel ET, Pfeffer K. Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium. Infect. Immun. 67, 3571–3579 (1999).
   PubMed Web of Science ®Google Scholar
• Mohan VP, Scanga CA, Yu K et al. Effects of tumor necrosis factor α on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. 69, 1847–1855 (2001).
   PubMed Web of Science ®Google Scholar
• Sugawara I, Yamada H, Kaneko H, Mizuno S, Takeda K, Akira S. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect. Immun. 67, 2585–2589 (1999).
   PubMed Web of Science ®Google Scholar
• Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 52, 1766–1772 (2005).
   PubMed Web of Science ®Google Scholar
• Sivakumar PV, Westrich GM, Kanaly S et al. interleukin-18 is a primary mediator of the inflammation associated with dextran sulfate sodium induced colitis: blocking interleukin-18 attenuates intestinal damage. Gut 50, 812–820 (2002).
   PubMed Web of Science ®Google Scholar
• Ten Hove T, Corbaz A, Amitai H et al. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-α production in mice. Gastroenterology 121, 1372–1379 (2001).
   PubMed Web of Science ®Google Scholar
• Wirtz S, Becker C, Blumberg R, Galle PR, Neurath MF. Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. J. Immunol. 168, 411–420 (2002).
   PubMed Web of Science ®Google Scholar
• Smeets RL, van de Loo FA, Arntz OJ, Bennink MB, Joosten LA, van den Berg WB. Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther. 10, 1004–1011 (2003).
   PubMed Web of Science ®Google Scholar
• Maecker HT, Hansen G, Walter DM, DeKruyff RH, Levy S, Umetsu DT. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyper-reactivity in a murine asthma model. J. Immunol. 166, 959–965 (2001).
   PubMed Web of Science ®Google Scholar
• Im SH, Barchan D, Maiti PK, Raveh L, Souroujon MC, Fuchs S. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J. 15, 2140–2148 (2001).
   PubMed Web of Science ®Google Scholar
• Furlan R, Martino G, Galbiati F et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J. Immunol. 163, 2403–2409 (1999).
   PubMed Web of Science ®Google Scholar
• Faggioni R, Jones-Carson J, Reed DA et al. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor α and IL-18. Proc. Natl Acad. Sci. USA 97, 2367–2372 (2000).
   PubMed Web of Science ®Google Scholar
• Fantuzzi G, Banda NK, Guthridge C et al. Generation and characterization of mice transgenic for human IL-18-binding protein isoform a. J. Leukoc. Biol. 74, 889–896 (2003).
   PubMedGoogle Scholar
• Tsutsui H, Kayagaki N, Kuida K et al. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 11, 359–367 (1999).
   PubMed Web of Science ®Google Scholar
• Fantuzzi G, Reed DA, Dinarello CA. IL-12-induced IFN-γ is dependent on caspase-1 processing of the IL-18 precursor. J. Clin. Invest. 104, 761–767 (1999).
   PubMed Web of Science ®Google Scholar
• Netea MG, Fantuzzi G, Kullberg BJ et al. Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. J. Immunol. 164, 2644–2649 (2000).
   PubMed Web of Science ®Google Scholar
• Vidal-Vanaclocha F, Fantuzzi G, Mendoza L et al. IL-18 regulates IL-1β-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc. Natl Acad. Sci. USA 97, 734–739 (2000).
   PubMed Web of Science ®Google Scholar
• Takeuchi D, Yoshidome H, Kato A et al. interleukin-18 causes hepatic ischaemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice. Hepatology 39, 699–710 (2004).
   PubMed Web of Science ®Google Scholar
• Hoshino K, Tsutsui H, Kawai T et al. Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J. Immunol. 162, 5041–5044 (1999).
   PubMed Web of Science ®Google Scholar
• Okamoto M, Kato S, Oizumi K et al. interleukin-18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood 99, 1289–1298 (2002).
   PubMed Web of Science ®Google Scholar
• Itoi H, Fujimori Y, Tsutsui H et al. Involvement of interleukin-18 in acute graft versus host disease in mice. Transplantation 78, 1245–1250 (2004).
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Yamagata T, Nozaki Y et al. Blockade of IL-18 receptor signaling delays the onset of autoimmune disease in MRL-Faslpr mice. J. Immunol. 173, 5312–5318 (2004).
   PubMedGoogle Scholar
• Cheung H, Chen NJ, Cao Z, Ono N, Ohashi PS, Yeh WC. Accessory protein-like is essential for IL-18-mediated signaling. J. Immunol. 174, 5351–5357 (2005).
   PubMed Web of Science ®Google Scholar
• Takagi H, Kanai T, Okazawa A et al. Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulfate colitis in mice. Scand. J. Gastroenterol. 38, 837–844 (2003).
   PubMedGoogle Scholar